Updates in Psoriatic Arthritis at EULAR 2022. Here are the topics I will be highlighting at the conference #psoriaticarthritis #EULAR2022 @RheumNow https://t.co/8Dd29GdUuz

• Updates in Psoriatic Arthritis at EULAR 2022 | RheumNow

WATCH: Can Dermatologists Help Detect Psoriatic Arthritis? Dr. Robert Chao reviews abstract OP0029 presented at #EULAR2022 in June. https://t.co/bAuCsVLJV2 https://t.co/BjUckSXIJ3

• https://bit.ly/3afZBY3

Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in disease activity when compared to MTX monotherapy. As expected, MTX+LEF less well tolerated. @RheumNow #EULAR2022 ABST#0078 https://t.co/Bo64QX3Bf9

Depression was the most prevalent comorbidity (31%), hypertension (26%) and uveitis the most common EMM (30%) in AS from the PSOAS cohort by @rheum_cat . Five clusters identified with depression and hypertension groups having higher disease activity #EULAR2022 @RheumNow OP0154 https://t.co/dpqaFD4Qzw

Risk factors associated with non-remission/LDA in PsA pts: Baseline TJC>3, SJC>5 CRP>10 HAQ>0.5 enthesitis/dactylitis BMI>30 sDMARD use @RheumNow #EULAR2022 ABST#POS0080

Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well.. @RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ

Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu

Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074